Literature DB >> 27730512

Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an Aβ1-42 Mouse Model of Alzheimer's Disease.

Tahir Ali1, Min Ju Kim1, Shafiq Ur Rehman1, Ashfaq Ahmad1, Myeong Ok Kim2.   

Abstract

Nanomedicine is an emerging research area. In this study, we investigated the neuroprotective efficacy of anthocyanin-loaded polyethylene glycol-gold nanoparticles (PEG-AuNPs) for enhancing the neuroprotective efficacy of anthocyanins in an amyloid beta (Aβ)1-42 mouse model of Alzheimer's disease. We observed that both anthocyanin-loaded PEG-AuNPs and anthocyanins treatment (12 μg/g/day for 14 days) ameliorated memory impairments in the Aβ1-42-injected mice. However, the anthocyanin-loaded PEG-AuNPs were more effective than free anthocyanins. Anthocyanin-loaded PEG-AuNPs protected pre- and post-synaptic proteins from Aβ1-42-induced synaptic dysfunction. Interestingly, the anthocyanin-loaded PEG-AuNPs also regulated the p-PI3K/p-Akt/p-GSK3β pathway and, as a result, prevented the hyperphosphorylation of tau protein at serines 413 and 404 in the Aβ1-42-injected mice. Western blot results of cytochrome c, Bax/Bcl2, caspases and poly (ADP-ribose) polymerase-1 expression levels, and immunohistochemical Nissl and Fluoro-Jade B staining also indicated that the anthocyanin-loaded PEG-AuNPs inhibited apoptosis and neurodegeneration in the Aβ1-42-injected mice. Our results suggest that the conjugation of dietary polyphenolic compounds with gold nanoparticles, such as anthocyanin-loaded PEG-AuNPs, is a novel approach that may represent an important and promising nanomedicine strategy to prevent age-associated neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer’s disease; Anthocyanin-PEG-gold nanoparticles; Nanomedicine; Neurodegeneration; Synaptic dysfunction

Mesh:

Substances:

Year:  2016        PMID: 27730512     DOI: 10.1007/s12035-016-0136-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  72 in total

Review 1.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

Authors:  D A Butterfield; J Drake; C Pocernich; A Castegna
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

Review 2.  Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.

Authors:  Celeste Roney; Padmakar Kulkarni; Veera Arora; Peter Antich; Frederick Bonte; Aimei Wu; N N Mallikarjuana; Sanjeev Manohar; Hsiang-Fa Liang; Anandrao R Kulkarni; Hsing-Wen Sung; Malladi Sairam; Tejraj M Aminabhavi
Journal:  J Control Release       Date:  2005-10-24       Impact factor: 9.776

3.  Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

Authors:  Tobias Engel; Félix Hernández; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2006-05-10       Impact factor: 6.167

Review 4.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Authors:  David J Begley
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

5.  Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway.

Authors:  Melita Salkovic-Petrisic; Florian Tribl; Manuela Schmidt; Siegfried Hoyer; Peter Riederer
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

6.  Soluble oligomers of amyloid-β peptide disrupt membrane trafficking of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction.

Authors:  Alfredo J Miñano-Molina; Judit España; Elsa Martín; Bruna Barneda-Zahonero; Rut Fadó; Montse Solé; Ramón Trullás; Carlos A Saura; José Rodríguez-Alvarez
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

Review 7.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

8.  Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Authors:  Oyinkan Sofola; Fiona Kerr; Iain Rogers; Richard Killick; Hrvoje Augustin; Carina Gandy; Marcus J Allen; John Hardy; Simon Lovestone; Linda Partridge
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

9.  Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus.

Authors:  Tahir Ali; Gwang Ho Yoon; Shahid Ali Shah; Hae Young Lee; Myeong Ok Kim
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

Review 10.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

View more
  23 in total

1.  Legumain Knockout Protects Against Aβ1-42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP.

Authors:  Runwen Chen; Qiyue Zhang; Yuxing Yan; Yuying Zhang; Tao Zhang
Journal:  Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.590

2.  Anthocyanins Improve Hippocampus-Dependent Memory Function and Prevent Neurodegeneration via JNK/Akt/GSK3β Signaling in LPS-Treated Adult Mice.

Authors:  Muhammad Sohail Khan; Tahir Ali; Min Woo Kim; Myeung Hoon Jo; Jong Il Chung; Myeong Ok Kim
Journal:  Mol Neurobiol       Date:  2018-05-19       Impact factor: 5.590

Review 3.  Protective Effects of Foods Containing Flavonoids on Age-Related Cognitive Decline.

Authors:  Kelsea R Gildawie; Rachel L Galli; Barbara Shukitt-Hale; Amanda N Carey
Journal:  Curr Nutr Rep       Date:  2018-06

4.  Graphene Oxide Quantum Dots Reduce Oxidative Stress and Inhibit Neurotoxicity In Vitro and In Vivo through Catalase-Like Activity and Metabolic Regulation.

Authors:  Chaoxiu Ren; Xiangang Hu; Qixing Zhou
Journal:  Adv Sci (Weinh)       Date:  2018-03-04       Impact factor: 16.806

Review 5.  State of the Art of Anthocyanins: Antioxidant Activity, Sources, Bioavailability, and Therapeutic Effect in Human Health.

Authors:  Noelia Tena; Julia Martín; Agustín G Asuero
Journal:  Antioxidants (Basel)       Date:  2020-05-23

6.  Cyanidin-3-glucoside as a possible biomarker of anthocyanin-rich berry intake in body fluids of healthy humans: a systematic review of clinical trials.

Authors:  Berner Andrée Sandoval-Ramírez; Úrsula Catalán; Sara Fernández-Castillejo; Anna Pedret; Elisabet Llauradó; Rosa Solà
Journal:  Nutr Rev       Date:  2020-07-01       Impact factor: 6.846

Review 7.  Maternal immune activation and neuroinflammation in human neurodevelopmental disorders.

Authors:  Velda X Han; Shrujna Patel; Hannah F Jones; Russell C Dale
Journal:  Nat Rev Neurol       Date:  2021-08-02       Impact factor: 42.937

Review 8.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

Review 9.  Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

Review 10.  Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences.

Authors:  Roxana Braga de Andrade Teles; Tâmara Coimbra Diniz; Tiago Coimbra Costa Pinto; Raimundo Gonçalves de Oliveira Júnior; Mariana Gama E Silva; Érica Martins de Lavor; Antonio Wilton Cavalcante Fernandes; Ana Paula de Oliveira; Fernanda Pires Rodrigues de Almeida Ribeiro; Amanda Alves Marcelino da Silva; Taisy Cinthia Ferro Cavalcante; Lucindo José Quintans Júnior; Jackson Roberto Guedes da Silva Almeida
Journal:  Oxid Med Cell Longev       Date:  2018-05-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.